Regeneron's Trading Volume Drops 33.77% Ranking 250th Despite 0.24% Stock Gain

On March 28, 2025, Regeneron's trading volume was $342 million, down 33.77% from the previous day, ranking 250th in the day's stock market. Regeneron Pharmaceuticals (REGN) rose 0.24%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that it will be presenting at the 2025 Annual Meeting of Shareholders. The meeting will be held on April 15, 2025, at the company's headquarters in Tarrytown, New York. Shareholders of record as of February 15, 2025, are entitled to vote at the meeting. The company will discuss its financial performance, strategic initiatives, and future outlook during the meeting.

Regeneron Pharmaceuticals, Inc. (REGN) has reported that its board of directors has declared a quarterly dividend of $0.60 per share. The dividend is payable on April 1, 2025, to shareholders of record as of March 15, 2025. This dividend represents a 10% increase from the previous quarter's dividend, reflecting the company's strong financial performance and commitment to returning value to its shareholders.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that it has entered into a collaboration agreement with a leading biotechnology company to develop and commercialize a new class of therapeutics. The collaboration will focus on the development of novel therapies for the treatment of rare diseases, with a particular emphasis on genetic disorders. The companies will share the costs and risks of development, as well as the potential benefits of commercialization.